Experience with olaparib in the treatment of recurrent ovarian epithelial cancer with mutations in the BRCA 1 and BRCA 2 genes

URN:NBN:SI:doc-MMGBLVBY2021Škof, Erikdocuments/doc/M/URN_NBN_SI_doc-MMGBLVBY_001.pdfdocuments/doc/M/URN_NBN_SI_doc-MMGBLVBY_001.txt125articlestr. 12-1610.25670/oi2021-002on1408-174165264899URN:NBN:SI:doc-MMGBLVBYslvOnkološki inštitut LjubljanaOnkologija (Ljubljana)BYBRCA 1/2BRCA 1/2 gene mutationepitelijski rak jajčnikovgenska mutacijaolaparibovarian epithelial cancerExperience with olaparib in the treatment of recurrent ovarian epithelial cancer with mutations in the BRCA 1 and BRCA 2 genesIzkušnje z zdravilom olaparib pri zdravljenju recidivnega epitelijskega raka jajčnikov z mutacijami v genih BRCA 1 in BRCA 2